

ORIGINAL ARTICLE

AFRICAN JOURNAL OF CLINICAL AND EXPERIMENTAL MICROBIOLOGY SEPTEMBER 2008 ISBN 1595-689X VOL 9 No 3

AJCEM/200786/20824

[-http://www.ajol.info/journals/ajcem](http://www.ajol.info/journals/ajcem)

COPYRIGHT 2008

AFR. J. CLN. EXPER. MICROBIOL. 9 (3): 157-165

MICROBIAL SPECTRUM OF PELVIC INFLAMMATORY DISEASES IN NGURU, NIGERIA

Okon, K.O., Ayilara R., Bello K., Uba A., Aniesona T. A.

Department of Medical Microbiology, University of Maiduguri Teaching Hospital Maiduguri.
Pathology/Obstetric & Gynecology department, Federal Medical Centre Nguru, Yobe State.
Department of Biological Sciences, Abubakar Rafawa Balewa University, Bauchi
Department of Veterinary Microbiology and Parasitology, University of Maiduguri

Corresponding Address: Okon, K.O. Department of Medical Microbiology University of Maiduguri Teaching Hospital P.M.B. 1414 Maiduguri. E-mail: okon_kenneth@yahoo.com

ABSTRACT

Pelvic inflammatory diseases, a leading gynecological problem worldwide, are associated with socio-economic and psychological costs. A retrospective study of 1350 high vaginal swabs analyzed between Jan-Dec. 2005, showed that 845 (62.8%) were positive for 9 microorganisms by culture/or wet preparation. Microbial growth was found in 645 (76.3%) cases. Polymicrobial growth was found in 90 (10.7%), fungal growth in 110 (13.0%) cases, and 3(0.4%) yielded anaerobic growth. *Staphylococcus aureus* accounted for 355 (42.0%) cases, followed by *Escherichia coli* 190 (22.5%), *Trichomonas vaginalis* 100 (11.8%) *Candida spp* and *Neisseria gonorrhoeae* 70 (8.3) and the least, *Pseudomonas spp* 5 (0.6%) Microbial-associated infection was prominent in the group 21-30 years old (46.6%) and 31-40 (23.9%) years respectively. Antibiotic susceptibility pattern showed that mean susceptibility greater than 50% were recorded with ofloxacin 80%, ceftazidime 80%, rifampicin 81.9% compared to mean susceptibility less than 50% recorded with trimethoprim-sulthamethoxazole 34.7%, and ampicillin 26.1%.

In conclusion, the reported microbial-associated infection in PID with a prevalence of 62.8% is of public health importance. Early diagnosis of causative agents and prompt institution of chemotherapeutic agents will help to prevent clinical complications that are expensive to treat.

Keywords: pelvic inflammatory diseases, microorganisms, antibiotic susceptibility.

INTRODUCTION

Pelvic inflammatory disease (PID), is an infection of the upper genital tract in women that include endometritis, parametritis, salpingitis, oophoritis, tubo-ovarian abscess and peritonitis (1,2). It accounts for 5-20% of hospital admissions for gynecological problems in general/gynecological clinics worldwide (3). In USA, infertility that affects approximately 10-15% of all couples attribute tubal damage due to

pelvic infection (4,5). Clinical presentation varies in severity, and ranges from sub clinical, asymptomatic infections exerting medical and psychological cost that include chronic pelvic pain, ectopic pregnancy and infertility (1). It has been associated with increase risk of ovarian cancer6-8. The pathogenesis is complex interaction of genetic, immunological and bacterial virulence factors (9).

The prevalence and incidence of PID varies greatly, because of significant misdiagnosed/or unreported cases. In developed countries, annual incidence of PID increased in women aged 15-45 years, with peak of infection in 20-24 years (10). Polymicrobial agents are associated and initiated pathogenesis of PID, particularly in presence of facultative aerobic and anaerobic bacterial isolates (11-14), with *Niesseria. Gonorrhoea* and *Chlamudia tracomatis* as leading pathogens, accounted for 60-80% in women of aged less than 25 years¹²⁻¹⁴. Other less pathogenic mycoplasma, and endogenous aerobic and anaerobic bacteria have also been implicated (15). Co-existence of sexually transmitted diseases (STD) etiological agent in genital tract predispose the women to acquisition of PID (1,16). Korn *et al* (17) reported that clinical presentation and course of PID in women with sy,ptomatiC HIV disease and/or severe immune suppression may be more aggressive than in HIV negative women.

Clinical diagnosis is rather difficult, as no single clinical and laboratory test in definite as gold standard, thus combination of test seems to improve sensitivity and specificity (18,19). Epidemiological and microbiological indices associated with PID are important source of preventable reproductive infertility in women, and other clinical sequelae. Little information is available on PID epidemiology in this environment, this there is no baseline in assessment of its relationship in case of infertility and HIV infection.

Early diagnosis/treatment of PID could stem down the effect on the fallopian tubes; and in case of microbe-related inflammation and tubal necrosis can similarly precedes manifestation of symptoms, especially in aetiological agent due to chlamydia³. Prompt diagnosis and institution of appropriate antibiotic therapy would prevent possible sequelae of PID. The retrospective study examined the aetiological spectrum in high vaginal swabs of pelvic inflammatory diseases in this environment.

MATERIALS AND METHODS

Study Site

The retrospective study was conducted in Federal Medical Center, Nguru, between Jan-Dec 2005, which involved the Pathology and Obsterictic/Gynecology departments. The patients folder presented at the general out-patients/gynecology clinic, with clinical complaint suggestive of pelvic inflammatory diseases, ranged from pelvic vaginal discharge to lower abdominal pain, with high vaginal swabs collected and sent for bacteriological analysis. Criteria of inclusion are consecutive non-duplicate high vaginal swabs, repeated swab analysis and mixed growth of doubtful significance were excluded. Information retrieved from the patients folder included age, sex, and clinical complaint.

Processing of the Specimens

The high vaginal swab was processed, with inoculation on Blood, Chocolate and Sabouraud agar plates, incubated at 37⁰C for 24hours. Bacterial/yeast were identified by standard bacteriological and mycological techniques (20-22). Yeasts were further identified by germ tube

test. Direct smear was prepared stained by Gram methods, and wet preparation of the specimen for parasitic examination. Antibiotic susceptibility testing was determined by disc diffusion²³, using the following antibiotic discs, ofloxacin (OFX), ciprofloxacin (CPX), pefloxacin (PEF), ceftazidime (CAZ), cefuroxime (CXM), rifampicin(RF), streptomycin(S), tetracycline (TET), trimethoprim sulthamethoxazole (SXT), ampicillin (AMP), gentamycin (CN), erythromycin (E), and augmentin(AU). The zone of inhibition of the disc was measured to determine whether resistant or sensitive in accordance to NCCLS guidelines (23). The mean susceptibility percentage of each antibiotic was calculated as the number of bacterial isolates susceptible divided by total number of bacterial isolates tested multiply by 100.

Data Analysis

Data and information retrieved from patients folders were entered into study database using SPSS version 13.0. The values were expressed as mean and percentage, and appropriate statistical package was used where necessary.

RESULTS

Of the 1350 high vaginal swabs results analyzed, 846 (62.8%) were positive for 9 microorganisms by culture/or wet preparation examination (7 bacterial pathogens, 1 fungus and 1 protozoan) as in table 1. The mean age of the patient was 22.4 ± 2.7 years. The ratio of gram-negative bacteria

ratio was 1:2:5. Monomicrobial growth was recorded in 645 (76.3%), polymicrobial growth in 90 (10.7%) and bacterofungal in 110 (12.0%) cases. Three (0.4%) cases yielded anaerobic growth.

Staphylococcus aureus was the most common for 355 (41.9%) cases, followed by *Escherichia coli* 190 (22.4%), *Trichomonas vaginalis* 100 (11.8%), *Neisseria gonorrhoeae* and *Candida spp* 70 (8.3%) respectively. Microbial-associated infection distribution, in accordance with the age group of the patients studied (table II), frequency of occurrence was predominant with the age group 21-30 (46.7%) and 31-40 (23.9%) years and least in 10-20 (8.1%) and >51 (6.4%) years respectively. There was a statistically significant difference between microbial infection and the age-group ($p < 0.05$). Similarly, there was a decreasing trend pattern in frequency of occurrence of microorganism and age-group.

Antibiotic susceptibility pattern of bacterial isolates as shown in table III, showed that mean susceptibility percentage greater than 50 was observed with ofloxacin, gentamycin, ciprofloxacin, pefloxacin, rifampicin, cefuroxime, ceftazidime, erythromycin and streptomycin, and less than 50 in trimethoprim-sulthamethoxazole, tetracycline, ampicillin, and augmentin.

Table I: Frequency of occurrence of Microorganisms Isolated

Microorganisms	Frequency of Occurrence (%)
Gram-positive bacteria (n=370)	
<i>Staphylococcus aureus</i>	355 (42.0)
<i>Streptococcus spp.</i>	15 (1.8)
Gram-negative bacteria (n=305)	
<i>Escherichia coli</i>	190(22.5)
<i>Neisseria gonorrhoea</i>	70(8.3)
<i>Klebsiella spp</i>	30(3.6)
<i>Proteus spp.</i>	10(1.2)
<i>Pseudomonas spp.</i>	5(0.6)
<i>Anaerobic bacteria</i>	3(0.4)
Fungi (n=70)	
<i>Candida spp</i>	70(8.3)
Parasites (n=100)	
<i>Trichomonas vaginalis</i>	100(11.8)
Total	848

Table II: Distribution of bacterial isolates according to age-group of patients studied

Age-group	S. aureus	Strep. Spp	KlebE.coli spp	Proteus spp	Pseud. spp	N.gonorrhoea	T. Vaginalis	Candida spp	Anae. bact	Total
10-20	30	-	-	10	-	1	5	16	7	69
21-30	115	10	15	95	8	-	40	74	37	396
31-40	100	3	8	45	2	-	15	8	21	205
41-50	75	2	5	25	-	1	10	2	5	125
>51	35	-	2	15	-	3	-	-	-	55
Total	355	15	30	190	10	5	70	100	70	848

Table III: Antibiotic susceptibility pattern of the bacterial isolates (% susceptibility)

BACTERIA ISOLATES	OF X	CN	CI P	PE F	SX T	AM P	RD	E	AU	S	CX M	CA Z	TE T
S.aureus	90	65	80	89	25	21	89	75	60	70	85	72	45
E.coli	82	70	75	83	43	26	78	65	72	73	78	80	54
Kleb spp	78	56	78	78	45	35	85	67	56	67	76	82	42
Strep spp	90	82	89	79	50	42	90	90	80	80	84	79	35
Proteus spp	75	67	75	74	35	22	76	69	67	67	73	80	45
Pseudo spp	60	42	73	67	20	12	65	52	45	45	75	82	38
N.gonorrhoeae	85	65	73	74	25	25	90	68	50	78	80	85	38
Mean Susceptibility(%)	80	63.7	77.6	77.7	34.7	26.1	81.9	69.4	69.4	68.6	78.7	80	42.2

DISCUSSION

Clinical significance of PID becomes pronounced because its association with sexually transmitted diseases/HIV/AIDS infections.

Particularly in asymptomatic individuals who may later present with various complications irrespective of the social and psychological cost (19,24). Consequently, a dramatic increase in the

the incidence of PID has led to a parallel increase in infertility (25).

The reported prevalence of microbial-associated infection in PID of 62.8% of our patients is high. Our report is similar to the rates reported in similar studies conducted in Sokoto (26) and Gombe (27) of same geographical zone. However, comparison of PID prevalence in studies conducted at different geographical location/countries might be rather difficult, because of certain inherent biases involved, particularly presence of PID-related infections (10,28-30). Similarly, PID prevalence are influenced by variation in case definition (particularly between different clinical settings), changes in disease chronicity associated with clinically mild Chlamydia infection, variation in health seeking behaviour and increase management of PID in outpatient setting (31,32).

The frequency of occurrence of microbial-associated infection was high in the age group of 21-30(46.7%) and 31-40(23.9%) years. This finding simply confirms reported findings that highest PID prevalence and highest rate of increase are associated and seen in the 16-24 years age groups, and substantial numbers of bacterial sexually transmitted infection are high these age group (16-19,3,6,19,33). Also PID accounts for approximately 60% of gynecological problems in women aged less than 25 years³⁴. High prevalence of PID episodes in sexually active age group, re-emphasises the correlation that co-existence of aetiological agent in the genital tract of the females predisposes to acquisition of PID (3,19,33-35). Some studies found demographic risk factors associated with

PID, like sexual activity at young age, racial, and both pre-delivery history and post-partum diagnosis of chlamydial and gonococci infections (36,37). However implication of these factors in this environment need further evaluation.

From the present study, 10 microorganism (8 bacterial pathogens, 1 fungal and 1 protozoan) were recorded. *S. aureus* was the commonest and accounted for 42%, polymicrobial infection was found in 10.7% of cases and fungal infection in 13.0% of cases. This pattern simply confirms polymicrobial spectrum aetiology associated with pathogenesis of PID (11-14). *S. aureus* (42.0%), and *E.coli* (22.5%) were predominant bacterial isolates in the study, these pathogens are most isolated in lower genital tract infections; and are responsible for a significant proportion of sexually transmitted diseases in Nigeria (26,38-40). The dominance of these bacterial pathogens as STI pathogens and their existence in the female genital tract clearly reaffirmed it as a predisposing factor in acquisition of PID (1,16). Polymicrobial infection with other organisms such as anaerobes or facultative aerobes may be initiated by gonorrhoea, chlamydia or both (4,5,15,35). The low frequency of occurrence of *N.gonorrhoeae* as evident in this study, might probably be due to variation in the studied population, method of microbial investigation, variation in severity of the diseases, sampling technology and site of sampling (40). Technically, *N. gonorrhoeae* is highly fastidious fragile organisms, isolation is dependent on viability of the organism in the specimen, prompt delivery to specimen, and suitability of isolation medium.

Trichomonas vaginalis with a prevalence of 11.6% in a center posed public health problem, because of close association of trichomoniasis with HIV infection (42-45). *T.vaginalis*, is an irritating protozoan and is a common parasitic sexually transmitted disease reported worldwide (45). It is associated with inflammation of the cervix that may mimic cervical tenderness associated with PID (42). Buve et al (43) reported that trichomoniasis incidence is higher in cities where there are higher number of HIV-positive individuals. The high prevalence of trichomoniasis and candidiasis observed in this study basically revealed close association of poor personal hygienic conditions especially among the low socio-economic class and transmitted sexually, particularly in cases of multiple sex partners (10), with high probability of PID infection.

The in-vitro antimicrobial susceptibility pattern of bacterial isolates revealed that mean percentage susceptibility of greater than 50% was observed with the fluoroquinolones (ofloxacin, ciprofloxacin, perfloxacin), cephalosporins (ceftazidime, cefuroxime) and rifampicin ; and those less than 50% observed with gentamycin, erythromycin, augmentine and streptomycin, and least susceptibility observed in tetracycline (42.2%) trimethoprim-sulphamethoxazole (34.7%) and ampicillin (2.1%). These antibiotic susceptibility patterns are similar to reports by other workers (26,27). The reduced susceptibility of antibiotics like ampicillin, tetracyclines and trimethoprim-sulphamethoxazole, clearly revealed the abuse of these agents by self-medication practice, a

common norm in most towns/cities in many developing countries.

The fluoroquinolones showed favourable in-vitro susceptibility pattern that could serve as drugs of choice in PID treatment/management. However, documented studies have reported emergence of fluoroquinolones-resistant *N.gonorrhoeae* (3). With considerable numbers of antibiotics resistant strains, particularly of *N. gonorrhoeae* to penicillin and cephalosporins (particularly 1st generation), the use of second-generation cephalosporins that possess extended spectrum activity over wide range of microorganisms associated with PID. From the in-vitro antibiotic susceptibility pattern of the study, gentamycin, erythromycin and streptomycin, could serve the antibiotic of choice considering the relative cost and also possess extended-spectrum activity. One of the greater threats to the efficacy of antibiotics is the presence/or emergence of resistant strain, thus, cautious approach is required in prescription/administration, as safeguard policy against possible emergence of multi-resistant strain in a remote city, like Nguru.

In conclusion, the prevalence of microbes-associated PID of 62.8%, is high. It is important that microorganisms associated with PID are diagnosed early and appropriate chemotherapeutic treatment/management commenced, as clinical complications are always very expensive to treat.

ACKNOWLEDGEMENT

We acknowledge the support and assistance of staff of the Pathology and Obstetric and Gynaecology departments, Federal Medical Centre, Nguru Yobe State.

REFERENCES

1. Banikarim C, Chacko MR. Pelvic inflammatory disease in adolescents. *Semin Pediatr Infect Dis* 2005 16(3); 175-80
2. Crossman SH. The challenge of pelvic inflammatory disease: Am Fam Physician 2006;73 (5):859-64.
3. Burnakis TG, Hildebrandt NB. Pelvic inflammatory diseases: a review with emphasis on antimicrobial therapy. *Rev Infect Dis* 1986 (8) 86-116
4. Ault KA, Faro S. Pelvic inflammatory disease, Current diagnosis criteria and treatment guidelines. *Postgrad Med* 1993, 93 (3);85-91.
5. Ehoton-Vlasak A. Infections and infertility. *Prim. Care Update Ob Gyns.* 2000, 7 (5):200-206
6. Westrom L. Incidence, prevalence and trends of acute pelvic inflammatory disease and its consequence industrialized countries. *Am J Obstet Gynecol* 1980 138:880-92
7. Buchan H, Vessey M, Goldacre M et al. Morbidity following pelvic inflammatory disease. *Br J Obstet Gynaecol* 1993; 100:558-62
8. Risch H, Howe G. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. *Cancer Epidemiol Biomarkers Prev* 1995; 4: 447-51.
9. Cohen C, Brunham R. Pathogenesis of Chlamydia induced pelvic inflammatory diseases *Sex Transm Infect* 1999;75:21-4.
10. Simms Stephenson JM. Pelvic inflammatory disease epidemiology and I: what do we know and what do we need to know? *Sex Transm Infect* 2000, 76:80-7
11. Heinonen PK and Miettinen A. Laparoscopic study on the microbiology and severity of acute pelvic inflammatory disease. *Eur J Obstet Reprod Biol* 1994; 57:85-90
12. Soper DE, Brockwell NJ, Dalton HP, Johnson D. Observations concerning the microbial etiology of acute salphngitis. *AM J Obstet Gynecol* 1994; 170: 1008-17.
13. Bevan CD, Johal BJ, Mumtaz G, Ridgway GL and Siddle NC. Clinical, laparoscopic and microbiologic findings in acute salpingitis: report on a United Kingdom cohort. *Br J Obstet Gynaecol* 1995;102:407-14.
14. Westrom L, Eschenbach D. Pelvic inflammatory disease, Sexually Transmitted Diseases, KK Holmes eds. New York, McGraw Hill:783-809.
15. Eschenbach DA 1980. Epidemiology and diagnosis of acute pelvic inflammatory disease. *Obstet Gynecol* 55;122s-153s.
16. Mardh P. Introductory address: microbial etiology of pelvic inflammatory disease. *Sex Transm Dis* 1984;11(S4): 428-9
17. Korn A, Landers D. Pelvic inflammatory disease and HIV-1 infection. In :Landers D, Sweet R, eds, pelvic inflammatory disease. Pittsburgh:Springer 1999.
18. Simms I, Stephenson J.M. Mallinson H, Peeling RW, et al Risk factors associated with pelvic inflammatory diseases. *Sex Transm infect* 2006, 10; 1136-8.
19. Munday PE. Pelvic inflammatory disease- an evidence based approach to diagnosis. *J Infect Dis* 2000; 40 31-40
20. Chessbrough M. Medical Laboratory Manual for Tropical Countries. English Language Books Society/Tropical Health Technology, Butterworth 1998
21. Haley LD, and Callaway CS. Laboratory Methods in Medical Mycology. 4th ed US Department of Health Education and Welfare, Public Health Service CDC Bureau of Laboratories.

22. Cowan ST, Cowan and Steel's Manual for the identification of Medical bacteria. 2nd ed Cambridge University Press, Cambridge 1985.
23. National Committee for Clinical Laboratory Standards, Performance standards for antimicrobial disc susceptibility tests. Approved standard. In; Balows A, Plot P, and Vanderpitte J (ed). Antimicrobial susceptibility testing. 2nd part of Bench-level procedure manual of basic bacteriology. WHO/LAB/87.1, 1987;21-38
24. Rein DB, Kassler WJ, Irwin KL, Rabiee L. Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing, but still substantial, *Obstet Gynecol* 2000, 95:397-402.
25. Torrington J. Pelvic inflammatory disease. *J Obstet Gynecol Neonatal Nurs* 1985;14(6 suppl) 21s-31s.
26. Emele FE, Anyiwo CE, and Fadahunsi AA. Etiological profile of vaginal infection in Sokoto, Nigeria. *Journal of Biomedical Investigation* 2004;2(2):57-62
27. Audu BM, and Kudi AA. Microbial isolates and antibiogram from endocervical swabs of patients with pelvic inflammatory disease. *J Obstet Gynecol* 2004;24:161-164.
28. Kwamwendo F, Forslin L, Bodin et al. Programmes to reduced pelvic inflammatory disease-the Swedish experience. *Lancet* 1998;351:25-8
29. Simms I, Catchpole M, Brugha et al. Epidemiology of Genital Chlamydia trachomatis in English and Wales. *Genitourin Med* 1996;73:122-6
30. Hiltunen-Back E, Roostila T, Kautiainen H et al. Rapid decrease of endemic gonorrhoea in Finland. *Sex Transm Dis* 1998;25:181-6
31. Wolner-Hassen P. Silent pelvic inflammatory disease: is it overstated? *Obstet Gynecol* 1995;86:321-5.
32. Howard M, Doherty J, Zimic-Vicentic M, et al. An epidemiologic study of a decrease in hospitalizations of pelvic inflammatory disease (PID) in two Canadian cities (1985-1995). Ninth International Symposium on Human Chlamydial Infection, Napa Valley, USA 1998.
33. Suss AL, Homel P, Hammerschlag M and Bromberg K. Risk Factors for pelvic inflammatory disease in inner-adolescents. *Sex Transm Dis* 2000;27:289-91.
34. Simms I, Stephenson JM, Mallinson H, Peeling RW et al. Risk factors associated with pelvic inflammatory diseases. *Sex Transm Infect* 2006;10:1136-8.
35. Brook I. Microbiology and management of polymicrobial female genital tract infections in adolescents. *J Pediatric Adolesc Gynecol* 2002, 15:217-26.
36. Ness RB, Kip KE, Hillier SL, Soper DE, Stamm, Sweet RL, Rice P, Richter HE. A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease *Am J Epidemiol* 2005; 162:585.
37. Mahon BE, Temkit M, Wang J, Rosenman MB, Katz BP. Pelvic inflammatory diseases during the post-partum year. *Infect Dis Obstet Gynecol* 2005, 13(4) 191-6
38. nyemekwe CC, Meludu SC, Dioka CE, Ofor US. Pattern and distribution of sexually transmitted disease in Lagos, Nigeria. *Journal of Biomedical Investigation*, 2004;2(2):63-67.
39. Chikwen Jo, Ukwandu NCD, Ayuba K, and Edike MA. Evaluation of gram stained smear of urine for predicting significant bacteruria. *J. Med Lab Sci* 1996;5:49-53.
40. Bello CSS, Elegba OY and Dada JO. Sexually transmitted disease in Northern Nigeria: Five years experience in a

- University Teaching Hospital Clinic. *Br J vener Dis* 1983;59:202-205
41. Ilze viberga. The clinical appearance of pelvic inflammatory disease in relation to use of intrauterine device in Latvia. *Digital comprehensive summaries of Uppsala Dissertation from the faculty of Medicine* 110, 2006; pg 12.
42. Moodley P, Wilkinson D, Connolly C, Moodley J, Sturm AW. *Trichomonas vaginalis* is associated pelvic inflammatory disease in women infected with human immunodeficiency virus. *CID* 2002;34:519-22.
43. Dunne RL, Dunn LA, Upcroft P, O Donoghue PJ, Upcroft JA. Drug resistance in sexually transmitted protozoan *Trichomonas vaginalis* *Cell Res* 2003;13:239-49
44. Buve A, Weiss HA, Laga M, *et al.* The epidemiology of trichomoniasis in women in four African cities. *AIDS*, 2001,15 (Supl 4): S89-96.
45. Sorvillo F, Smith L, Kerndt P, Ash L. *Trichomonas vaginalis*, HIV and African-Americans. *Emerg Infect Dis* 2001;7:927-32
46. Chavalitshewinkoon-Petmitr P, Ramdja M, Kajorndechakiat S, RK, Deny WA, Wilairat P. In vitro susceptibility of *Trichomonas vaginalis* to AT-specific minor groove binding drugs. *J Antimicrob Chemother* 2003;52:287-9.